aTyr Pharma Inc
ATYR0.750USD
+0.047+6.67%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
73.49MMarket Cap
LossP/E TTM
More Details of aTyr Pharma Inc Company
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).
aTyr Pharma Inc Info
Ticker SymbolATYR
Company nameaTyr Pharma Inc
IPO dateMay 07, 2015
CEOShukla (Sanjay S)
Number of employees56
Security typeOrdinary Share
Fiscal year-endMay 07
Address10240 Sorrento Valley Road
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18587318389
Websitehttps://www.atyrpharma.com/
Ticker SymbolATYR
IPO dateMay 07, 2015
CEOShukla (Sanjay S)
Company Executives of aTyr Pharma Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Sanjay S. Shukla, M.D.
Dr. Sanjay S. Shukla, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
146.92K
--
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
56.00K
+833.33%
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
9.75K
+62.50%
Dr. Svetlana Lucas, Ph.D.
Dr. Svetlana Lucas, Ph.D.
Independent Director
Independent Director
6.00K
--
Dr. Paul R. Schimmel, Ph.D.
Dr. Paul R. Schimmel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jill M. Broadfoot
Ms. Jill M. Broadfoot
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Eric S. Benevich
Mr. Eric S. Benevich
Independent Director
Independent Director
--
--
Ms. Nancy E. Denyes, J.D.
Ms. Nancy E. Denyes, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Sara A. Zaknoen, M.D.
Dr. Sara A. Zaknoen, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Sanjay S. Shukla, M.D.
Dr. Sanjay S. Shukla, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
146.92K
--
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
56.00K
+833.33%
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
9.75K
+62.50%
Dr. Svetlana Lucas, Ph.D.
Dr. Svetlana Lucas, Ph.D.
Independent Director
Independent Director
6.00K
--
Dr. Paul R. Schimmel, Ph.D.
Dr. Paul R. Schimmel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jill M. Broadfoot
Ms. Jill M. Broadfoot
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
15.00%
Federated Hermes Global Investment Management Corp.
10.76%
BlackRock Institutional Trust Company, N.A.
6.10%
The Vanguard Group, Inc.
5.75%
UBS Financial Services, Inc.
4.43%
Other
57.96%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
15.00%
Federated Hermes Global Investment Management Corp.
10.76%
BlackRock Institutional Trust Company, N.A.
6.10%
The Vanguard Group, Inc.
5.75%
UBS Financial Services, Inc.
4.43%
Other
57.96%
Shareholder Types
Shareholders
Proportion
Investment Advisor
34.41%
Investment Advisor/Hedge Fund
20.32%
Hedge Fund
5.55%
Research Firm
2.07%
Individual Investor
1.43%
Pension Fund
0.48%
Venture Capital
0.32%
Bank and Trust
0.28%
Other
35.14%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
239
62.14M
74.65%
-8.47K
2025Q3
238
62.15M
75.06%
-5.22M
2025Q2
207
66.51M
74.92%
+4.54M
2025Q1
151
62.77M
67.36%
+2.91M
2024Q4
133
55.86M
70.25%
+2.89M
2024Q3
108
48.56M
73.86%
-253.71K
2024Q2
103
48.81M
69.97%
+6.29M
2024Q1
101
42.52M
69.38%
-4.61M
2023Q4
100
41.92M
73.68%
+4.09M
2023Q3
99
37.82M
71.76%
+1.48M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
13.35M
13.63%
+457.14K
+3.55%
Jun 30, 2025
Federated Hermes Global Investment Management Corp.
14.67M
14.97%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.34M
5.45%
+3.83M
+253.28%
Jun 30, 2025
The Vanguard Group, Inc.
4.66M
4.75%
+648.31K
+16.18%
Jun 30, 2025
UBS Financial Services, Inc.
1.75M
1.78%
+138.23K
+8.60%
Jun 30, 2025
State Street Investment Management (US)
1.24M
1.27%
+872.35K
+237.50%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.10M
2.14%
+1.17M
+126.13%
Jun 30, 2025
Millennium Management LLC
1.60M
1.63%
+1.16K
+0.07%
Jun 30, 2025
Schimmel (Paul R Ph.D.)
1.10M
1.12%
+100.00K
+9.99%
Mar 01, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
State Street SPDR S&P Biotech ETF
0.04%
Direxion Daily S&P Biotech Bull 3X Shares
0.02%
iShares Micro-Cap ETF
0.01%
Vanguard US Momentum Factor ETF
0.01%
Pacer WealthShield ETF
0.01%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
View more
State Street SPDR S&P Biotech ETF
Proportion0.04%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.02%
iShares Micro-Cap ETF
Proportion0.01%
Vanguard US Momentum Factor ETF
Proportion0.01%
Pacer WealthShield ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of aTyr Pharma Inc?
The top five shareholders of aTyr Pharma Inc are:
Fidelity Management & Research Company LLC holds 13.35M shares, accounting for 13.63% of the total shares.
Federated Hermes Global Investment Management Corp. holds 14.67M shares, accounting for 14.97% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.34M shares, accounting for 5.45% of the total shares.
The Vanguard Group, Inc. holds 4.66M shares, accounting for 4.75% of the total shares.
UBS Financial Services, Inc. holds 1.75M shares, accounting for 1.78% of the total shares.
Fidelity Management & Research Company LLC holds 13.35M shares, accounting for 13.63% of the total shares.
Federated Hermes Global Investment Management Corp. holds 14.67M shares, accounting for 14.97% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.34M shares, accounting for 5.45% of the total shares.
The Vanguard Group, Inc. holds 4.66M shares, accounting for 4.75% of the total shares.
UBS Financial Services, Inc. holds 1.75M shares, accounting for 1.78% of the total shares.
What are the top three shareholder types of aTyr Pharma Inc?
The top three shareholder types of aTyr Pharma Inc are:
Fidelity Management & Research Company LLC
Federated Hermes Global Investment Management Corp.
BlackRock Institutional Trust Company, N.A.
Fidelity Management & Research Company LLC
Federated Hermes Global Investment Management Corp.
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of aTyr Pharma Inc (ATYR)?
As of 2025Q4, 239 institutions hold shares of aTyr Pharma Inc, with a combined market value of approximately 62.14M, accounting for 74.65% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.41%.
What is the biggest source of revenue for aTyr Pharma Inc?
In --, the -- business generated the highest revenue for aTyr Pharma Inc, amounting to -- and accounting for --% of total revenue.
